| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment |
|
Turkish Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia |
|
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation |
Aplastic Anemia |
| The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria |
|
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
|
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| The evolving role of next generation sequencing in myelodysplastic syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
|
Cells |
Myelodysplastic Syndromes (MDS) |
| The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
